Malaysia at a glance
- Population
- 36.0 million 2025
- Life expectancy at birth
- 76.8 years, 2024
- People aged 65 and over
- 8.0 % of people, 2025
- Health spending per person
- 450 US$ per person, 2023
- Doctors
- 2.34 per 1,000 people, 2023
Updated
Reviewed by Vidhi Upadhyay
Malaysia Retinal Disease Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$19.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $24.7 Mn | — | — |
| 2025 (base) | $26.3 Mn | +$1.6 Mn | — |
| 2026 (forecast) | $27.9 Mn | +$1.7 Mn | +6.4% |
| 2027 (forecast) | $29.7 Mn | +$1.8 Mn | +13.2% |
| 2028 (forecast) | $31.6 Mn | +$1.9 Mn | +20.5% |
| 2029 (forecast) | $33.7 Mn | +$2.0 Mn | +28.2% |
| 2030 (forecast) | $35.8 Mn | +$2.2 Mn | +36.4% |
| 2031 (forecast) | $38.1 Mn | +$2.3 Mn | +45.1% |
| 2032 (forecast) | $40.5 Mn | +$2.4 Mn | +54.4% |
| 2033 (forecast) | $43.1 Mn | +$2.6 Mn | +64.3% |
| 2034 (forecast) | $45.9 Mn | +$2.8 Mn | +74.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $26.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $45.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, indication and end user (see all) |
| Key players | Regeneron Pharmaceuticals, Roche, Bayer AG, Novartis AG, Samsung Bioepis (see all) |
| Regulator in Malaysia | NPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Retinal disease drugs, mostly anti-VEGF injections, treat wet macular degeneration and diabetic eye disease.
Key segments of the retinal Disease Drugs market include drug (Aflibercept, Faricimab and Ranibizumab) and indication (Wet AMD, Diabetic Macular Edema and Retinal Vein Occlusion).
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.
Longer-acting treatments, home-based care and screening in emerging markets give the retinal Disease Drugs market room to grow.
High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the retinal Disease Drugs market.
The retinal Disease Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.[2]
[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
[2] Ministry of Health Malaysia. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for retinal Disease Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.
What doctors and scientists are doing in Retinal Disease Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
Malaysia · 1 shared keyword
Malaysia · 1 shared keyword
Malaysia · 1 shared keyword
Malaysia
Malaysia
Malaysia
Digital Health · Malaysia
Medical Devices · Malaysia
OTC & Nutraceuticals · Malaysia
Medical Devices · Malaysia
Medical Devices · Malaysia
OTC & Nutraceuticals · Malaysia